201 related articles for article (PubMed ID: 23428347)
1. Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells.
Kim JE; Jin DH; Lee WJ; Hur D; Wu TC; Kim D
Pharmacol Res; 2013 May; 71():23-33. PubMed ID: 23428347
[TBL] [Abstract][Full Text] [Related]
2. Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination.
Tseng CW; Monie A; Wu CY; Huang B; Wang MC; Hung CF; Wu TC
J Mol Med (Berl); 2008 Aug; 86(8):899-908. PubMed ID: 18542898
[TBL] [Abstract][Full Text] [Related]
3. Immune mechanism of the antitumor effects generated by bortezomib.
Chang CL; Hsu YT; Wu CC; Yang YC; Wang C; Wu TC; Hung CF
J Immunol; 2012 Sep; 189(6):3209-20. PubMed ID: 22896634
[TBL] [Abstract][Full Text] [Related]
4. Enhancing dendritic cell vaccine potency by combining a BAK/BAX siRNA-mediated antiapoptotic strategy to prolong dendritic cell life with an intracellular strategy to target antigen to lysosomal compartments.
Kang TH; Lee JH; Noh KH; Han HD; Shin BC; Choi EY; Peng S; Hung CF; Wu TC; Kim TW
Int J Cancer; 2007 Apr; 120(8):1696-703. PubMed ID: 17230516
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in vitro.
Jung SH; Lee YK; Lee HJ; Choi NR; Vo MC; Hoang MD; Lim MS; Nguyen-Pham TN; Kim HJ; Lee JJ
Exp Hematol; 2014 Apr; 42(4):274-81. PubMed ID: 24407159
[TBL] [Abstract][Full Text] [Related]
6. Irradiation Enhances Abscopal Anti-tumor Effects of Antigen-Specific Immunotherapy through Regulating Tumor Microenvironment.
Chang MC; Chen YL; Lin HW; Chiang YC; Chang CF; Hsieh SF; Chen CA; Sun WZ; Cheng WF
Mol Ther; 2018 Feb; 26(2):404-419. PubMed ID: 29248428
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitor AR-42 enhances E7-specific CD8⁺ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination.
Lee SY; Huang Z; Kang TH; Soong RS; Knoff J; Axenfeld E; Wang C; Alvarez RD; Chen CS; Hung CF; Wu TC
J Mol Med (Berl); 2013 Oct; 91(10):1221-31. PubMed ID: 23715898
[TBL] [Abstract][Full Text] [Related]
8. Antigen-specific CD8+ T lymphocytes generated from a DNA vaccine control tumors through the Fas-FasL pathway.
Cheng WF; Lee CN; Chang MC; Su YN; Chen CA; Hsieh CY
Mol Ther; 2005 Nov; 12(5):960-8. PubMed ID: 15979942
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
[TBL] [Abstract][Full Text] [Related]
10. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen.
Wiethe C; Dittmar K; Doan T; Lindenmaier W; Tindle R
J Immunol; 2003 Mar; 170(6):2912-22. PubMed ID: 12626542
[TBL] [Abstract][Full Text] [Related]
11. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
12. DNA vaccine with α-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells.
Kim D; Hung CF; Wu TC; Park YM
Vaccine; 2010 Oct; 28(45):7297-305. PubMed ID: 20817010
[TBL] [Abstract][Full Text] [Related]
13. Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade).
Schumacher LY; Vo DD; Garban HJ; Comin-Anduix B; Owens SK; Dissette VB; Glaspy JA; McBride WH; Bonavida B; Economou JS; Ribas A
J Immunol; 2006 Apr; 176(8):4757-65. PubMed ID: 16585569
[TBL] [Abstract][Full Text] [Related]
14. Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents.
Zeng Q; Peng S; Monie A; Yang M; Pang X; Hung CF; Wu TC
Hum Gene Ther; 2011 Jul; 22(7):809-19. PubMed ID: 21128743
[TBL] [Abstract][Full Text] [Related]
15. Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells.
Li HS; Liu C; Xiao Y; Chu F; Liang X; Peng W; Hu J; Neelapu SS; Sun SC; Hwu P; Watowich SS
Sci Signal; 2016 Sep; 9(447):ra94. PubMed ID: 27678219
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death.
Kim JH; Kang TH; Noh KH; Bae HC; Kim SH; Yoo YD; Seong SY; Kim TW
Immunol Lett; 2009 Jan; 122(1):58-67. PubMed ID: 19135479
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity.
Kim TW; Hung CF; Kim JW; Juang J; Chen PJ; He L; Boyd DA; Wu TC
Hum Gene Ther; 2004 Feb; 15(2):167-77. PubMed ID: 14975189
[TBL] [Abstract][Full Text] [Related]
18. Uptake routes of tumor-antigen MAGE-A3 by dendritic cells determine priming of naïve T-cell subtypes.
Moeller I; Spagnoli GC; Finke J; Veelken H; Houet L
Cancer Immunol Immunother; 2012 Nov; 61(11):2079-90. PubMed ID: 22562379
[TBL] [Abstract][Full Text] [Related]
19. The combination of Pleurotus ferulae water extract and CpG-ODN enhances the immune responses and antitumor efficacy of HPV peptides pulsed dendritic cell-based vaccine.
Li J; Li J; Aipire A; Luo J; Yuan P; Zhang F
Vaccine; 2016 Jun; 34(31):3568-75. PubMed ID: 27211038
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments.
Kang TH; Lee JH; Bae HC; Noh KH; Kim JH; Song CK; Shin BC; Hung CF; Wu TC; Park JS; Kim TW
Immunol Lett; 2006 Aug; 106(2):126-34. PubMed ID: 16844231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
